Funded by a $24,000,000  grant through the federal
New Frontiers in Research Program, the TRanslational Initiative to ​DErisk NeuroTherapeutics
(TRIDENT) platform is offers a transformative approach to the preclinical evaluation of neurotherapeutics.  TRIDENT will dramatically improve the odds of success of  neurotherapeutics in clinical trials for the benefit of humans across the globe.